First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Brief description of study
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study because it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States. The main goal of this research study is to determine the maximum tolerated dose (MTD) of an investigational drug and see if the drug is safe when given to people with malignant solid tumors.
Clinical Study Identifier: s19-01575
ClinicalTrials.gov Identifier: NCT03917381
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
